Please ensure Javascript is enabled for purposes of website accessibility

Why Biogen Stock Is Crashing Today

By George Budwell - Updated Apr 14, 2019 at 6:01PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Biogen's closely-watched Alzheimer's drug fails to move in the needle in two late-stage trials.

What happened

Shares of biotech heavyweight Biogen (BIIB -0.42%) are in a tailspin this morning after the company and its partner Eisai (ESALF 2.56%) reported that they would discontinue two late-stage trials for Alzheimer's disease drug candidate aducanumab.

Biogen and Eisai noted in the press release that their decision is based on the recommendation of an independent data-monitoring committee following a futility analysis. The committee reportedly found that aducanumab was "unlikely to meet the primary endpoints" in either study. Biogen's shares are down by a little over 27% as of 9:53 a.m. EDT in the wake of this major clinical failure. 

A human neuron

Image source: Getty Images.

So what

Biogen is in a bit of a pickle following this clinical setback. The biotech's core multiple sclerosis franchise is in decline, and its top growth driver -- Spinraza -- could face some stiff competition from a rival gene therapy soon.

Unfortunately, the company put far too much faith in this extremely risky clinical asset, leaving it wholly unprepared to adequately deal with these various headwinds. The consequence is that Biogen will probably have to scramble to find a fresh source of growth through either a licensing deal or an acquisition -- and soon. 

Check out the latest earnings call transcript for Biogen.

Now what

Is Biogen's dramatic sell-off warranted? The answer is undoubtedly yes. Alzheimer's disease drug candidates have failed 99% of the time over the last 15 years, and there wasn't much reason to believe that aducanumab was going to be any different in this regard. Aducanumab, after all, belongs to a class of drugs that have shown -- quite literally -- zero efficacy in Alzheimer's across numerous pivotal trials. 

Having said that, Biogen now has no choice but to search for an alternative path forward -- and that means the company should be beating the bushes today in search of a new growth product. If Biogen can find the right acquisition target, the narrative surrounding this struggling biotech could change for the better in the blink of an eye. Stay tuned. 

George Budwell has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Biogen. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Biogen Inc. Stock Quote
Biogen Inc.
BIIB
$217.28 (-0.42%) $0.92
Eisai Co., Ltd. Stock Quote
Eisai Co., Ltd.
ESALF
$46.10 (2.56%) $1.15

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
377%
 
S&P 500 Returns
123%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/08/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.